Wealth Enhancement Advisory Services’s Syndax Pharmaceuticals SNDX Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$471K	Sell	19,950 -2,595	-12%	-$54K	﹤0.01%	2740
2026 Q1	$567K	Buy	22,545 +2,350	+12%	+$51.1K	﹤0.01%	2221
2025 Q4	$411K	Buy	20,195 +7,310	+57%	+$128K	﹤0.01%	2635
2025 Q3	$212K	Buy	+12,885	New	+$169K	﹤0.01%	3086
2025 Q2	–	Sell	-13,172	Closed	-$162K	–	3476
2025 Q1	$162K	Buy	+13,172	New	+$186K	﹤0.01%	2670

Other funds holding SNDX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HRCM

Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

Wealth Enhancement Advisory Services's SNDX Position: Q2 2026 in Review

Wealth Enhancement Advisory Services reduced its Syndax Pharmaceuticals (SNDX) stake by 12% in Q2 2026, selling an estimated $54K and leaving 19,950 shares worth $471K. The position accounts for ﹤0.01% of the portfolio, ranked #2740.

Wealth Enhancement Advisory Services first reported a position in SNDX in Q1 2025 and has held it in 5 quarters since. The position peaked at $567K in Q1 2026. 242 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

Wealth Enhancement Advisory Services held 19,950 shares of Syndax Pharmaceuticals worth $471K as of Q2 2026.
Wealth Enhancement Advisory Services sold 2,595 Syndax Pharmaceuticals shares in Q2 2026, an estimated $54K.
Syndax Pharmaceuticals made up ﹤0.01% of Wealth Enhancement Advisory Services's portfolio in Q2 2026, its #2740 holding.
Wealth Enhancement Advisory Services first reported a position in Syndax Pharmaceuticals in Q1 2025 and has held it in 5 quarters since.
Wealth Enhancement Advisory Services's Syndax Pharmaceuticals position peaked at $567K in Q1 2026.
242 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q2 2026, filed 15 Jul 2026.